The technique could help study how genetic variants in different people affect which genes are expressed during infection or response to drugs ,and could also increase efficiency of single-cell experiments, assisting research into transplants, personalized medicine, and malaria.
While the test, which exploits glycan biology to detect current infection with SARS-CoV-2 is undergoing clinical assessment, the company is working in parallel to ensure that mass production can be rolled out once validation is completed.
The AMP PGx Working Group developed the guideline with organizational representation from the College of American Pathologists (CAP) and the Clinical Pharmacogenetics Implementation Consortium (CPIC).
While the decrease was most pronounced in lung cancer testing and diagnoses, the oncology tracker also recorded reduced diagnosis rates in colorectal, ovarian, and breast cancers over the same period.
NIH is urging all scientists and inventors with a rapid testing technology to compete in a national COVID-19 testing challenge for a share of up to $500 million over all phases of development.
The DETECT-A study was the largest liquid biopsy study in a general population with no history of the disease. Together, the blood test plus standard-of-care testing had a combined sensitivity of 52.1%, double the rate of standard screening alone.
The researchers found that rare variation in the gene TET2 nearly doubled the risk of developing diseases like Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD).
Using saliva for COVID-19 testing has several advantages when compared to collection of nasopharyngeal swabs: it does not require specialized swabs or tubes, is far less uncomfortable for the patient, and may even be done independently by the patient.
The platform comprises a cartridge-housed microfluidic chip that carries out isothermal amplification of viral nucleic acids from nasal swab samples, which are then detected using the smartphone camera.
Veracyte plans to make the non-invasive, blood-based test available as a complement to its Envisia Genomic Classifier to aid in the diagnosis and treatment of patients with IPF.